---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-028082"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:31:40.921603+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix reports Q4 2021 DEXTENZA revenue $12.2M, up 77% YoY; net loss $3.9M

## Summary
- DEXTENZA net product revenue $12.2M in Q4, +77% vs Q4 2020; full year $43.5M vs $17.4M.
- Net loss $(3.9)M ($0.05 basic EPS) includes $15.9M non-cash gain; full year net loss $(6.6)M.
- Cash $164.2M at Dec 31, 2021; expects to fund operations through 2023.
- OTX-TKI (wet AMD) US Phase 1 fully enrolled; interim data expected H2 2022.
- OTX-DED (dry eye) Phase 2 met primary endpoint; positive top-line data Dec 2021.

## SEC filing metadata
- accession: 0001104659-22-028082
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465922028082/0001104659-22-028082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465922028082/tm227780d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-028082
- JSON: https://secwatch.observer/filing/0001104659-22-028082.json
- Plain text: https://secwatch.observer/filing/0001104659-22-028082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.